Tyrosine Kinase Inhibitors: all 10,469 studies that test it
Page 58 of 105. Open to participants first (1,907), then studies with results posted, then the rest; newest registration first within each.
- Savolitinib Plus Osimertinib Versus Platinum-based Doublet Chemotherapy in Participants With Non-Small Cell Lung Cancer Who Have Progressed on Osimertinib TreatmentActive, not recruitingNCT05261399Phase 3
- Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR MutationsCompletedNCT05258279Phase 2
- Phase I/II Study of SY-3505 in Patients With ALK-positive Advanced Non-small Cell Lung CancerStatus unknownNCT05257512Phase 1/2
- A Phase II Clinical Trial of Fruquintinib as Third Line Treatment in Advanced Pancreatic CancerStatus unknownNCT05257122Phase 2
- Phase 1/2 Study of Silevertinib (BDTX-1535) in Patients With Glioblastoma or Non-Small Cell Lung Cancer With EGFR MutationsActive, not recruitingNCT05256290Phase 1/2
- Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast CancerStatus unknownNCT05255523Phase 2
- Efficacy and Safety of Furmonertinib in EGFR-Mutant, PD-L1+ Patients With Locally Advanced or Metastatic NSCLC (FUTURE)Status unknownNCT05255406Phase 2
- PK Study to Assess Drug-drug Interaction Between Sitravatinib and a P-gp Inducer and an Inhibitor.CompletedNCT05255276Phase 1
- To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid TumorsCompletedNCT05253053Phase 1/2
- Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant NeratinibActive, not recruitingNCT05252988Phase 2
- Effect of Montmorillonite Power or Loperamide on the Pharmacokinetics of Pyrotinib in Healthy SubjectsCompletedNCT05252546Phase 1
- To Evaluate the Safety, Pharmacokinetic and the Effect of Food After Administration of ABN401 in Healthy Adult VolunteersCompletedNCT05248074Phase 1
- Tofacitinib in the Treatment of Rheumatoid Arthritis-related Interstitial Lung Disease.Status unknownNCT05246293Phase 2
- A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101)Active, not recruitingNCT05245968Phase 1
- Study Comparing Pharmacokinetics of Different Formulations of Evobrutinib in Healthy ParticipantsCompletedNCT05245396Phase 1
- A Study to Evaluate KIN-3248 in Participants With Advanced Tumors Harboring FGFR2 and//or FGFR3 Gene AlterationsTerminatedNCT05242822Phase 1
- GB5121 in Adult Patients With Relapsed/Refractory CNS LymphomaTerminatedNCT05242146Phase 1
- (Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion MutationsTerminatedNCT05241873Phase 1
- A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to TreatmentCompletedNCT05241834Phase 1
- BARIcitinib Cognitive Emotional and Neural signaTuRETerminatedNCT05238896Phase 4
- SMMART Adaptive Clinical Treatment (ACT) TrialWithdrawnNCT05238831Early Phase 1
- A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200CompletedNCT05238337Phase 1
- Janus Kinase-STAT Inhibition to Reduce APOL1 Associated Kidney DiseaseCompletedNCT05237388Phase 2
- Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma （SPARE-02）CompletedNCT05235100Phase 2
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 2WithdrawnNCT05233410Phase 3
- Study of Anlotinib With Chemoradiation for Patients With Locally Advanced Nasopharyngeal CarcinomaStatus unknownNCT05232552Phase 2
- A Study to Evaluate the Efficacy and Safety of Orelabrutinib in Adult Patients With Immune ThrombocytopeniaStatus unknownNCT05232149Phase 2
- Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.Active, not recruitingNCT05230810Phase 1/2
- A Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Sitravatinib as Maintenance Therapy for ES-SCLCActive, not recruitingNCT05228496Phase 2
- Margetuximab Plus Tucatinib and Capecitabine in HER2-positive Metastatic Breast CancerWithdrawnNCT05227131Phase 2
- An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced GastrointestinalStatus unknownNCT05225844Phase 2
- A Study to Learn About the Study Medicine (Called Lorlatinib) in People With Liver DysfunctionCompletedNCT05224609Phase 1
- Effect of Imatinib in Advance Liver Fibrosis PatientsStatus unknownNCT05224128Phase 1/2
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerCompletedNCT05223088Phase 2
- A Study to Evaluate ERAS-801 in Patients With Recurrent Glioblastoma (THUNDERBBOLT-1)Active, not recruitingNCT05222802Phase 1
- Study With Infigratinib in Subjects With Advanced Solid and CNS Tumors or Recurrent or Progressive Low-Grade Glioma With Selected FGFR1-3 AlterationsWithdrawnNCT05222165Phase 1/2
- Safety of XELOX Combined With GLS-010 and Lenvatinib in Advanced AFP-positive Gastric Cancer PatientsStatus unknownNCT05221775Phase 1
- Anlotinib Plus Sintilimab as First-line Treatment for Advanced Non Clear Cell Renal Cell CarcinomaActive, not recruitingNCT05220267Phase 2
- TACE Combined With Lenvatinib Versus TACE Sequential Lenvatinib in the Treatment of Intermediate/Advanced Liver CancerStatus unknownNCT05220020Phase 3
- Topical Ruxolitinib Evaluation in Chronic Hand Eczema Study 1WithdrawnNCT05219864Phase 3
- The Bioequivalence Study of Two Sunitinib Products in Capsules 50 mg in Healthy Volunteers Under Fasting ConditionsStatus unknownNCT05218616Phase 1
- Fruquintinib Hepatic Impairment StudyCompletedNCT05216367Phase 1
- Fruquintinib Renal Impairment StudyCompletedNCT05216354Phase 1
- Pemigatinib in Subjects With Adenosquamous Carcinoma of the PancreasWithdrawnNCT05216120Phase 2
- A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of PatientsStatus unknownNCT05214976Phase 2
- Adavosertib and Gemcitabine in Advanced PancreaticWithdrawnNCT05212025Phase 2
- A Single-Arm Clinical Study of Pemigatinib in the Treatment of Advanced Non-Small Cell Lung Cancer PatientsStatus unknownNCT05210946Not applicable
- Alflutinib Versus Alflutinib Plus Chemotherapy for NSCLCStatus unknownNCT05209256Phase 2/3
- Safety and Efficacy of Eribullin or Eribulin Combined With Anlotinib in Metastatic Breast CancerCompletedNCT05206656Phase 2
- A Study of Tazemetostat in Combination With Various Treatments in Participants With Blood Cancer.WithdrawnNCT05205252Phase 1/2
- Zanubrutinib and CAR T-cell Therapy for the Treatment of Recurrent or Refractory Aggressive B-cell Non-Hodgkin's Lymphoma or Transformed Indolent B-cell LymphomaActive, not recruitingNCT05202782Phase 2
- A Single-Arm Phase II Exploratory Clinical Study of Pemigatinib in the Treatment of Advanced Gastric and Colorectal Cancer Patients With FGFR Alterations Who Have Failed Standard TherapyStatus unknownNCT05202236Phase 2
- A Phase II Study of Zanubrutinib, Lenalidomide Plus R-CHOP as the First-line Treatment for Diffused Large B-cell LymphomaStatus unknownNCT05200312Phase 2
- An Open-Label, Single-Dose, Parallel-Group Study of the Pharmacokinetics and Safety of EQ143CompletedNCT05199610Phase 1
- A Study of Azenosertib (ZN-c3) and Niraparib in Subjects With Platinum-Resistant Ovarian CancerCompletedNCT05198804Phase 1/2
- A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health VolunteersCompletedNCT05192369Phase 1
- HMPL-760 in Relapsed/Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT05190068Phase 1
- A Study to Evaluate Efficacy and Safety of Zanubrutinib With R-CHOP in Newly Diagnosed Non-GCB DLBCL Patients With Double ExpressionActive, not recruitingNCT05189197Phase 2
- Rapid Sequencing of Approved Therapies in Patients With Metastatic or Unresectable Clear Cell Renal Cell CarcinomaCompletedNCT05188118Early Phase 1
- (Summit) A Study to Evaluate the Efficacy and Safety of CGT9486 Versus Placebo in Patients With Indolent or Smoldering Systemic MastocytosisActive, not recruitingNCT05186753Phase 2
- Ensatinib Treat Second-generation ALK-TKI Resistance After Second-generation ALK-TKI ResistanceStatus unknownNCT05178511Phase 2
- Tislelizumab Combined With Sitravatinib as Consolidation Treatment Following Concurrent Chemoradiation in Patients With Locally Advanced, Unresectable NSCLCTerminatedNCT05176925Phase 2
- A Phase 1 Study to Assess the Safety, Tolerability, Pharmacokinetics of DZD8586 in Healthy Adult ParticipantsCompletedNCT05176873Phase 1
- HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHLWithdrawnNCT05176691Phase 1
- Avelumab, Palbociclib and Axitinib in Advanced RCCWithdrawnNCT05176288Phase 2
- Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/RearrangementsActive, not recruitingNCT05174650Phase 2
- A Phase Ib/II Clinical Study Evaluating HMPL-453 Tartrate as Monotherapy and in Combination With Chemotherapy or Toripalimab in Advanced Solid TumorsCompletedNCT05173142Phase 1/2
- Surufatinib in Advanced Hepatocellular Carcinoma Based on Single-cell Sequencing of Tumor SamplesStatus unknownNCT05171439Phase 2
- Neoadjuvant Combination Therapy of Lenvatinib and TACE for Transplant-Eligible Large Hepatocellular Carcinoma PatientsCompletedNCT05171335Phase 2
- Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCCStatus unknownNCT05171309Phase 2
- A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)Active, not recruitingNCT05170204Phase 3
- Minnelide and Osimertinib for the Treatment of Advanced EGFR Mutated Non-Small Cell Lung CancerActive, not recruitingNCT05166616Phase 1
- Adjuvant Targeted-therapy for Patients With Resected High-risk EGFR-mutant Stage IB-IIA Non-small Cell Lung CarcinomaStatus unknownNCT05165355Phase 2
- Osimertinib With or Without Savolitinib as 1L in de Novo MET+, EGFR+ NSCLCActive, not recruitingNCT05163249Phase 2
- Clinical Trial to Assess Bioequivalence of Lazertinib Between Two Formulations in Healthy Volunteers.CompletedNCT05162274Phase 1
- Crizotinib Continuation Clinical StudyActive, not recruitingNCT05160922Phase 4
- A Study to Assess the Effect of Food on the Absorption and Bioavailability of PBI-200CompletedNCT05160389Phase 1
- Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male SubjectsCompletedNCT05159895Phase 1
- Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCCCompletedNCT05156970Phase 2
- Tislelizumab（Anti PD-1), Lenvatinib and GEMOX Transformation in the Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerActive, not recruitingNCT05156788Phase 2
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)Active, not recruitingNCT05156281Phase 3
- Neratinib Dose Escalation Regimen for HER2 Positive Early Breast CancerStatus unknownNCT05154396Phase 2
- (HARMONY) Study of BLU-701 in EGFR-mutant NSCLCTerminatedNCT05153408Phase 1
- Early Changes in Pain, Disease Activity, and Ultrasound Evidence of Inflammatory Synovitis in Patients Receiving JAK-inhibitor vs. TNF-inhibitor Therapy for Active Rheumatoid Arthritis: A Feasibility Study.Status unknownNCT05153200Phase 4
- A Study of Pembrolizumab With Lenvatinib in Women With Advanced Uterine CarcinosarcomaActive, not recruitingNCT05147558Phase 2
- Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-1)Active, not recruitingNCT05147220Phase 3
- Study of TY-9591 in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR MutationCompletedNCT05146219Phase 2
- A Clinical Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsules Versus Paclitaxel as Weekly Treatment of Relapsed Platinum-resistant Ovarian CancerStatus unknownNCT05145218Phase 3
- Lorlatinib Continuation StudyActive, not recruitingNCT05144997Phase 4
- Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic PhaseActive, not recruitingNCT05143840Phase 2
- Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine CarcinomasStatus unknownNCT05142865Phase 2
- Fruquintinib in the Treatment of Soft Tissue SarcomaStatus unknownNCT05142631Phase 2
- Ruxolitinib and Methylprednisolone as a First-line Treatment for Macrophage Activation SyndromeStatus unknownNCT05137496Phase 3
- AK105 Combined With Anlotinib in Patients With Cervical CancerActive, not recruitingNCT05137171Phase 2
- Evaluate the Efficacy and Safety of SHR1459 Tablets in Patients With Primary Membranous NephropathyActive, not recruitingNCT05136456Phase 2
- Combination of Capmatinib + Spartalizumab in Advanced Oesogastric AdenocarcinomaSuspendedNCT05135845Phase 2
- HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE FailureStatus unknownNCT05135364Phase 2
- Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCCStatus unknownNCT05134532Phase 2
- A Prospective Phase II Efficacy and Safety Study of Anlotinib in Metastatic or Locally Advanced Pheochromocytoma/ Paraganglioma : Open-label Single-arm, Exploratory TrialStatus unknownNCT05133349Phase 2
- Clinical Study of the Efficacy and Safety of Transhepatic Arterial Chemoembolization Combined With Tislelizumab and Lenvatinib in Patients With Advanced Unresectable Hepatocellular CarcinomaStatus unknownNCT05131698Early Phase 1